Sequenom Corp fka SQNM

[surf1944]

8:31AM Sequenom licenses worldwide rights to develop age-related macular degeneration diagnostic test (SQNM) 4.13 : Co announces an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine, obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration. The license agreement covers extensive intellectual property rights for the most significant AMD-related genetic variants that have been confirmed in multiple clinical studies around the world. The portfolio of intellectual property being licensed has been consolidated from major US universities who have spearheaded genetic and clinical AMD research during the last decade.